Functional consequences of stem and progenitor cell heterogeneity

整体项目总结 这个项目汇集了五名造血研究人员，他们一直在合作 解决单个造血干细胞和祖细胞(HSPC)如何的根本问题 在体内平衡和应激条件下促进血液生产的调节。它创建了一个 研究人员实验室开发的用于跟踪单个克隆的补充技术的集合 从而模拟不同克隆行为在不同条件下对造血量的贡献 条件。此外，它使用创新的工具来操纵特定的基因分子调节器。 表达，以测试哪些分子驱动特定的HSPC行为。这些都是在以下环境中测试的 炎症和遗传毒性应激，并评估它们改变竞争关系的能力 具有携带血液疾病相关等位基因的克隆的正常HSPC已知在老年人类中积累。 模型、物种、发育时间和分子参数(mRNA、meDNA、 NcRNA，染色质状态)通过已建立的公共数据库和分析工具共享 独一无二的强大手段，以高分辨率定义造血过程。通过提供一个 维持互动、共享数据和技术并创建解决冲突论坛的机制 数据，这一PO1将有助于创建一份造血“路线图”，从而在特定情况下采取干预措施 分子经穴可以调节血细胞的产生，增强造血再生和限制 在疾病环境中异常的克隆生长。

OVERALL PROJECT SUMMARY This program brings together five hematopoiesis investigators who have been working collaboratively to address the fundamental question of how individual hematopoietic stem and progenitor cells (HSPC) are regulated to contribute to the production of blood under homeostatic and stress conditions. It creates a collective of complementary technologies developed in the investigator's laboratories to track individual clones in vivo and thereby to model how distinct clonal behaviors contribute to hematopoietic output under varying conditions. Furthermore, it employs innovative tools for manipulating specific molecular regulators of gene expression to test which molecules drive specific HSPC behaviors. These are tested in the context of inflammatory and genotoxic stress and are evaluated for their ability to alter the competitive relationship of normal HSPC with clones bearing blood disease associated alleles known to accumulate in the aging human. The cross comparison of models, species, time in development and molecular parameters (mRNA, meDNA, ncRNA, chromatin state) shared through an established common database and analytic tools provide a uniquely powerful means of defining with high resolution the process of hematopoiesis. By providing a mechanism to sustain interaction, share data and techniques and create a forum for resolution of conflicting data, this PO1 will facilitate the creation of a hematopoiesis `roadmap' whereby interventions at specific molecular waypoints can modulate blood cell production to enhance hematopoietic regeneration and limit aberrant clonal outgrowth in settings of disease.